---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-23-000035"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T12:21:43.133886+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biogen Q3 GAAP loss $0.47/sh, revenue $2.53B; updates FY guidance, highlights LEQEMBI

## Summary
- Revenue $2.53B (+1% YoY, +3% CC); GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 (-9% YoY).
- LEQEMBI FDA approval for Alzheimer's, ZURZUVAE for PPD approved; Reata acquisition closed.
- Fit for Growth cost savings program of $1B initiated to improve bottom line.
- Full-year 2023 guidance updated; new launches expected to drive growth.
- Subcutaneous LEQEMBI and tau-directed ASO (BIIB080) show clinical potential.

## SEC filing metadata
- accession: 0000875045-23-000035
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504523000035/0000875045-23-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504523000035/biib-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-23-000035
- JSON: https://secwatch.observer/filing/0000875045-23-000035.json
- Plain text: https://secwatch.observer/filing/0000875045-23-000035.txt

## Key facts
- Earnings Releases
  BIOGEN INC. reported third quarter ended September 30, 2023 results: revenue $2,530 million, EPS GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36.
  - Period: third quarter ended September 30, 2023
  - Revenue: $2,530 million
  - EPS: GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36
  - Result: reported results
  source text: --- EX-99.1 (EX-99.1) --- Press Release Cambridge, Mass. – Nov. 8, 2023 Biogen reports third quarter 2023 results and updates full year 2023 guidance Third quarter revenue $2,530 million; GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 Poised for leadership in Alzheimer's disease with ongoing LEQEMBI launch and development of tau-directed ASO (BIIB080) • New
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504523000035/0000875045-23-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.